NCT05027594: Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma

• PERK Inhibitor

• NCT05027594: Phase 1: Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma

Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma

This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable.

Sponsor

Nerviano Medical Sciences

---

ClinicalTrials.gov Identifier: NCT05027594

Official Title: A Phase I Dose Escalation Study of NMS-03597812, a PERK Inhibitor, in Adult Patients With Relapsed or Refractory Multiple Myeloma

First Posted : August 30, 2021

Click here to see details on ClinicalTrials.gov

---

Drug: NMS-03597812

Drug: NMS-03597812 + dexamethasone

---

PERK Inhibitor NMS-03597812

PERK Inhibitor NMS-03597812 (Code C184373)

NMS 03597812

NMS-03597812

NMS03597812

PERK Inhibitor NMS-03597812

---

Location

United States, Massachusetts

United States, New York

United States, North Carolina